Literature DB >> 20033646

Methods to identify and characterize different NK cell receptors and their ligands.

Dikla Lankry1, Roi Gazit, Ofer Mandelboim.   

Abstract

Different cellular immune responses are modulated by the cross talk between activating and inhibitory signaling pathways initiated via different cell surface receptors. Similarly, the killing of NK cells is controlled by multiple activating and inhibitory surface receptors. In humans, the major NK triggering receptors, identified so far, include NKp80, 2B4 NKG2D, and CD16 and the natural cytotoxic receptors (collectively named NCRs) include NKp46, NKp44, and NKp30. The two major families of MHC-specific inhibitory receptors identified in humans are the Ig superfamily (KIR and LIR) and the C-type lectin (CD94/NKG2A) receptor superfamily. The different inhibitory receptors show diverse specificity and discriminate between different class I MHC proteins. Much is known about the function and expression patterns of the different NK cell receptors, but the ligand identity of several of the activating NK cell receptors is yet to be discovered. This chapter introduces several research tools that can be used to uncover the identities of different ligands for NK cell receptors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20033646     DOI: 10.1007/978-1-60761-362-6_17

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  1 in total

1.  Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack.

Authors:  Chamutal Gur; Yara Ibrahim; Batya Isaacson; Rachel Yamin; Jawad Abed; Moriya Gamliel; Jonatan Enk; Yotam Bar-On; Noah Stanietsky-Kaynan; Shunit Coppenhagen-Glazer; Noam Shussman; Gideon Almogy; Angelica Cuapio; Erhard Hofer; Dror Mevorach; Adi Tabib; Rona Ortenberg; Gal Markel; Karmela Miklić; Stipan Jonjic; Caitlin A Brennan; Wendy S Garrett; Gilad Bachrach; Ofer Mandelboim
Journal:  Immunity       Date:  2015-02-10       Impact factor: 31.745

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.